<DOC>
	<DOCNO>NCT01605097</DOCNO>
	<brief_summary>This study investigate feasibility use technology ultrasound guide HDR brachytherapy focally increase dose region within prostate heavily infiltrated cancer . Such region , refer dominant intraprostatic lesion ( DIL ) visualize use diffusion contrast enhance MRI employ endo-rectal coil . The magnetic resonance ( MR ) image fuse plan transrectal ultrasound ( TRUS ) prior brachytherapy procedure design dose distribution encompass malignant volume high prescription dose . By nature , brachytherapy subvolumes receive ( example ) 125 % prescription dose 150 % prescription dose . With TRUS-guided TRUS-planned HDR area manipulate coincide DIL . The limit dose escalation reach whole prostate external beam dose 81-86 Gy still failure rate intermediate high risk disease unacceptable . There much interest focal dose escalation TRUS-guided HDR brachytherapy perfectly suit achieving .</brief_summary>
	<brief_title>High Dose Rate Prostate Brachytherapy : Dose Escalation Dominant Intra-prostatic Nodule</brief_title>
	<detailed_description>Methods : If dominant nodule visualize dynamic contrast enhance ( DCE ) MRI , contour 3D image fuse plan TRUS study do preparation brachytherapy ( type : seed HDR ) . The patient 's treatment consist standard combine external beam ( 4600 centiGray ( cGy ) 23 fraction ) HDR brachytherapy boost ( 2 fraction 1000 cGy give day 5 15 external beam course ) . During HDR treatment plan manipulate normally occur high dose region ( 125 % , 150 % ) position site identify disease . Normally approximately 60 % prostate volume receive 125 % dose 30 % receive 150 % . By ensure inherent dosimetry favor treatment know cancer , region prostate would `` underdosed '' . HDR treatment perform general anesthesia patient procedure . Statistical Analysis : This feasibility study data report descriptive include frequency DIL visualize population , DIL volume compare total prostate volume , isodose encompass DIL without violate dose constraint adjacent organ ( urethra bladder ) . Toxicity monitor efficacy assessed repeat DCE MRI 12 month biopsy 30 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>histologically proven adenocarcinoma prostate intermediate high risk prostate cancer Intermediate risk prostate cancer patient must : Clinical stage ≤ T2c , Gleason score = 7 initial prostate specific antigen ( iPSA ) ≤ 20 , Gleason score ≤ 6 iPSA &gt; 10 ≤ 20 . High risk patient may Clinical stage T3 Gleason score 810 PSA &gt; 20 ng/ml fit general anesthetic . unilateral disease either palpable nodule cluster positive biopsy single region suggest presence dominant nodule . estimate life expectancy least 10 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2. contraindication interstitial prostate brachytherapy . coumadin therapy must able stop safely 7 day . must contraindication MRI Does meet stag criterion intermediate high risk prostate cancer Does localize high volume intraprostatic disease unfit general anesthetic MRI contraindicate unable stop blood thinner Life expectancy &lt; 10 year</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>prostate neoplasm</keyword>
	<keyword>interstitial radiation</keyword>
	<keyword>High dose rate prostate brachytherapy</keyword>
	<keyword>dose escalation</keyword>
</DOC>